Catalog No.: PC-49649Not For Human Use, Lab Use Only.
E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.
E-CFCP is a novel long-acting nucleotide reverse transcriptase inhibitor (NRTI) against HBV, shows potent activity against HBV WTD1 and HBV WTC2 with IC50 of 1.8 and 0.7 nM, respectively.
E-CFCP exhibited potent anti-HBV activity in HBV-exposed PXB-cells, blocked the production of intracellular HBV-DNA by IC50qPCR_cell with IC50 of 0.01 nM.
E-CFCP exerted potent activity against ETV-resistant and ADV-resistant HBV variants, HBVETV-RL180M/S202G/M204V (IC50SB_cell=57.2 nM), also potent against HBVADV-RA181T/N236T (IC50SB_cell=6.2 nM).
E-CFCP does not shows significant mtDNA synthesis inhibition in PBMCs and PXB-cells.
Once-daily peroral E-CFCP administration over 2 weeks (0.02∼0.2 mg/kg/day) reduced HBVWTC2-viremia by 2–3 logs in PXB-mice without significant toxicities and the reduction persisted over 1–3 weeks following treatment cessation.
